Tenofovir Alafenamide (Taf) Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 25 mg TAF per tablet
Reference Brands: Vemlidy® (EU & US)
Category:
Hepatitis
Tenofovir Alafenamide (TAF) is a 25 mg oral antiviral used to treat chronic Hepatitis B and HIV-1 infections. It provides higher drug levels inside cells with fewer side effects on kidneys and bones compared to TDF. Marketed as Vemlidy® for Hepatitis B, TAF is approved by FDA and EMA and widely used in the US and EU. It’s a key option for pharma B2B suppliers and healthcare providers managing viral infections.
Tenofovir Alafenamide (TAF) is available in Tablet
and strengths such as 25 mg TAF per tablet.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tenofovir Alafenamide (TAF) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tenofovir Alafenamide (TAF) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tenofovir Alafenamide (TAF) is a next-generation nucleotide reverse transcriptase inhibitor (NRTI) used for the treatment of chronic Hepatitis B virus (HBV) infection and HIV-1. Available as oral tablets, typically in 25 mg strength, TAF delivers higher intracellular concentrations of the active drug with lower plasma exposure, improving safety and reducing kidney and bone side effects compared to Tenofovir Disoproxil Fumarate (TDF). Marketed under the brand name Vemlidy® (for HBV) and as part of combination therapies for HIV, TAF is FDA- and EMA-approved, widely used by pharma B2B suppliers and healthcare providers in the US and EU.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing